文献速递妇科

HE4在晚期高级别浆液性卵巢癌中的预后价值:分析新辅助化疗期间HE4动力学并与CA125比较预测手术结局和复发

Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
PubMed 文献 · Gynecol Oncol · 2024-01-03

这项在韩国Severance医院开展的回顾性队列研究纳入123例晚期高级别浆液性卵巢癌、输卵管癌或原发性腹膜癌患者,比较新辅助化疗(NACT)期间及术后HE4与CA-125动力学对中间性肿瘤减灭术(IDS)结局的预测价值。结果显示NACT期间CA-125和HE4均显著下降,但仅CA-125下降百分比与化疗反应评分(CRS)显著相关;术前HE4异常与残留病变风险比2.72(95%CI=1.27-5.79)相关。结论认为监测HE4或CA-125预后价值有限,但术前HE4水平可能有助于识别手术减灭不理想风险较高的患者,需进一步前瞻性研究。

要点

  • NACT期间CA-125和HE4均显著下降,但仅CA-125下降百分比与CRS显著相关(p=0.004)。
  • 术前HE4异常与残留病变风险比2.72(95%CI=1.27-5.79)相关,而CA-125正常化无此预测作用。
  • NACT期间CA-125或HE4下降百分比与残留病变或复发均无显著关联。

核心结论

  • 在晚期高级别浆液性卵巢癌接受NACT后IDS的患者中,监测HE4或CA-125水平的预后价值较低。
  • 术前HE4水平可能有助于识别手术减灭不理想风险较高或可能需要更广泛手术的患者。
  • 需要进一步前瞻性研究探索临床、影像和生物学参数的最终组合的预后效用,特别是使用基于人工智能的模型。

研究设计与样本

  • 回顾性队列研究,在韩国首尔Severance医院开展,纳入123例2015年4月至2020年7月诊断的高级别浆液性上皮性卵巢癌、输卵管癌或原发性腹膜癌女性。
  • 评估三个结局:大网膜化疗反应评分(CRS)、IDS后残留病变和复发。
  • 收集并分析基线、NACT周期期间及术前术后的临床、影像和生物学参数。

主要发现

  • NACT期间CA-125水平中位数从1612降至85.55 U/mL(p<0.001),HE4水平中位数从514.7降至87.7 pmol/L(p<0.001)。
  • 术前至术后仅HE4降低显著,中位数从77.3降至62.0 pmol/L(p<0.001)。
  • 4.1%的患者对NACT无反应(化疗耐药),65.9%为部分反应;55例(44.7%)观察到残留病变;90例(73.2%)复发,中位无进展生存期15.28个月。
  • NACT期间CA-125下降百分比与CRS(大网膜)显著相关:CRS为3和2时CA-125下降中位数分别为96.4(IQR=8.3)和93.7(12.2),高于评分1的68.3(34.1),差异有统计学意义(p=0.004);HE4下降百分比与CRS无显著关联。
  • NACT期间CA-125或HE4下降百分比与残留病变或复发均无显著关联。

关键数值与推荐

  • CRS为3时NACT期间CA-125下降中位数96.4(IQR=8.3),CRS为2时93.7(12.2),CRS为1时68.3(34.1),差异p=0.004。
  • 术前HE4异常与残留病变风险比2.72(95%CI=1.27-5.79)。
  • NACT期间CA-125水平中位数从1612降至85.55 U/mL(p<0.001),HE4从514.7降至87.7 pmol/L(p<0.001)。
  • 术前至术后HE4中位数从77.3降至62.0 pmol/L(p<0.001)。

临床怎么用

  • 作者认为术前HE4水平可能有助于识别手术减灭不理想风险较高或可能需要更广泛手术的患者。
  • 作者结论认为监测HE4或CA-125水平在NACT后IDS患者中预后价值较低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the prognostic value of human epididymis protein 4 (HE4) kinetics during and after neoadjuvant chemotherapy (NACT) cycles compared with cancer antigen 125 (CA-125), in predicting the surgical outcomes of interval debulking surgery (IDS) in patients with advanced-stage, high-grade serous ovarian cancer. METHODS: This retrospective cohort study was conducted at Severance Hospital in Seoul, South Korea and involved 123 women with high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who were diagnosed between April 2015 and July 2020. Three outcomes were considered: the chemotherapy response score (CRS) by omentum, residual disease after IDS, and recurrence. Other clinical, imaging, and biological parameters at baseline, during NACT cycles, and pre- and postoperative time were collected and analyzed. RESULTS: We observed a substantial and gradual decrease in both CA-125 level (median from 1612 to 85.55 U/mL; p < 0.001) and HE4 level (514.7 to 87.7 pmol/L; p < 0.001) during NACT cycles, while pre-to-postoperative reduction was only significant for HE4 (median from 77.3 to 62.0 pmol/L (p < 0.001)). Of the total patients, 4.1% showed no response to NACT (chemoresistance) and 65.9% had a partial response. Residual disease was observed in 55 (44.7%) patients. Recurrence occurred in 90 patients (73.2%), with a median progression-free survival of 15.28 months. The percent reduction in CA-125 level- but not HE4 - during NACT was significantly associated with CRS (by omentum); the reduction in CA-125 during NACT cycles was higher when the CRS was found to be 3 and 2 (median = 96.4 [IQR = 8.3] and 93.7 [12.2] respectively) compared to score 1 (68.3 [34.1]), and the difference was statistically significant (p = 0.004). However, no significant association was observed between the percent reduction in CA-125 or HE4 levels during NACT and residual disease or recurrence. The normalization of HE4 - but not CA-125 - before surgery was predictive for surgery outcome; that is, an abnormal preop HE4 level was associated with a residual disease risk ratio of 2.72 (95% CI = 1.27-5.79). CONCLUSION: Monitoring HE4 or CA-125 levels has low prognostic value in patients with advanced-stage, high-grade serous ovarian cancer who are treated with NACT followed by IDS. However, the preoperative level of the HE4 biomarker may be useful in identifying patients at higher risk for suboptimal cytoreductive surgery or who may require more extensive surgery. Further prospective studies are warranted to explore the prognostic utility of eventual combinations of clinical, radiological, and biological parameters, notably by using artificial intelligence-based models.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. AlSomairi A, Himayda S, Altelmesani A, et al. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125. Gynecol Oncol. 2024. PMID: 38176127. doi:10.1016/j.ygyno.2023.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。